Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indiplon
- Development stage
- Preclinical
- Lead developer
- Neurocrine Biosciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Indiplon is a novel, investigational nonbenzodiazepine hypnotic sedative of the pyrazolopyrimidine class developed for the treatment of insomnia. It was designed in two oral formulations—immediate-release for sleep onset and modified-release for sleep maintenance. Indiplon acts as a positive allosteric modulator at GABA-A receptors, with high affinity and selectivity for alpha1 subunit-containing GABA-A receptors, enhancing the inhibitory action of gamma-aminobutyric acid (GABA) in the brain. The drug has a short elimination half-life (1.5–2 hours), making it suitable for minimizing next-day residual effects. Despite demonstrating efficacy and tolerability in clinical trials involving over 7,500 participants, development was discontinued after an FDA approvable letter requested additional data[1][2][3][5][6][8].
- Brand names
- Indiplon
- Other names
- Indiplon-d3Indiplon-d-3Indiplon-d 3325715-02-4
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on Indiplon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Indiplon.